Evicenter
P&T meetings

Tirabrutinib

Primary central nervous system lymphoma

Regulatory submission
NDA submitted December 2025
Last updated
72 sources

Clinical evidence

Lymphomatosis cerebri case report

3 evidence topics · 2 sources

Objective
Location and study date

No evidence found.

Study design
Eligibility criteria

Not applicable.

Treatment
Study outcomes
Rationale for using radiological response as an observed outcome

Not applicable.

Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets

Not applicable.

Results
Participant disposition

No evidence found.

Baseline characteristics
Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary

This single case describes five months of complete radiological resolution after starting tirabrutinib. The observation does not establish response frequency, long-term disease control, or comparative benefit in lymphomatosis cerebri.